Novartis, with the backing of Blackstone Life Sciences, has launched Anthos Therapeutics, a new biopharmaceutical company focused on advancing next-generation targeted therapies for high-risk cardiovascular patients. The new company is based in Cambridge, MA.   As part of this launch, Novartis has licensed to Anthos MAA868, an antibody directed at Factor XI and XIa, key components of the intrinsic coagulation pathway. A large unmet medical need exists for next-generation anti-thrombotic therapie...